Nuklearmedizin 2020; 59(02): 93-94
DOI: 10.1055/s-0040-1708133
Leuchttürme
Leuchtturm-Sitzung 3: Theranostics
© Georg Thieme Verlag KG Stuttgart · New York

The impact of prior therapies on overall survival in mCRPC patients receiving Lu-PSMA-617 therapy. A WARMTH retrospective multicenter trial

H Ahmadzadehfar
1   University Hospital Bonn, Nuklearmedizin, Bonn
,
K Rahbar
2   University Hospital Muenster, Nuklearmedizin, Münster
,
RP Baum
3   Center for Precision Radiomolecular Oncology, Bad Berka
,
C Gerke
1   University Hospital Bonn, Nuklearmedizin, Bonn
,
C Kratochwil
4   University Hospital Heidelberg, Nuklearmedizin, Heidelberg
,
H Ilhan
5   University Hospital Munich, Nuklearmedizin, Munich
,
M Sathekge
6   University of Pretoria & Steve Biko Academic Hospital, Nuklearmedizin, Pretoria
,
L Kabasakal
7   Istanbul University, Nuklearmedizin, Istanbul
,
F. O Garcia-Perez
8   Instituto Nacional de Cancerología Mexico, Nuklearmedizin,, Mexico
,
K Kairemo
9   Docrates Cancer Center, Nuklearmedizin, Helsinki
,
M Maharaj
10   Nuklearmedizin, Durban
,
D Paez
11   International Atomic Energy Agency, Nuclear Medicine and Diagnostic Imaging Section, Vienna
,
I Virgolini
12   Medical University Innsbruck, Nuklearmedizin, Innsbruck
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2020 (online)

Also available at
 

Ziel/Aim The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH performed a multicentre analysis of more than 300 patients to evaluate OS. The study’s primary aim was to determine the OS rate and evaluate the predictive factors of OS and the impact of prior therapieson it.

Methodik/Methods The data of 631 mCRPC patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy and patients for whom a chemotherapy was contraindicated

Ergebnisse/Results The analysis included the data of 453 patients, with a median age of 71.3 years. At the time of analysis, 138 patients (30 %) were still alive. Fifty-four percent of patients had received both abiraterone and enzalutamide; 76.2 % and 27.2 % had a history of chemotherapy with docetaxel and cabazitaxel, respectively. Twenty-two percent had had Ra-223. Patients without any prior chemotherapy showed a significantly longer OS (14.3 months vs. 10.7 months; p:0.015). There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. Apart from significantly shorter OS in patients who underwent therapy with enzalutamide concurrently with the PSMA therapy, the other prior therapies did not have any significant impact on OS.

Schlussfolgerungen/Conclusions CRPC patients receiving Lu-PSMA-617 therapy, who had not received prior chemotherapy, had better OS than patients with a history of chemotherapy. Apart from ongoing therapy with enzalutamide, other prior chemotherapy had no impact on OS